Pfizer and Arvinas give disappointing breast cancer drug to Rigel
Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast cancer drug to Rigel Pharmaceuticals. They decided last year that ...
May 12, 2026 11:00 AM EDT Deals Pfizer and Arvinas give disappointing breast cancer drug to Rigel Lei Lei Wu News Reporter Pfizer has turned $1 billion into $35 million. The New York-based pharma company and its partner Arvinas are selling rights to their recently approved breast … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that